Get the Stockscreener App
384.02
0.26%
1.00
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
West Pharmaceutical Services Inc stock is traded at $384.02, with a volume of 511.42K.
It is up +0.26% in the last 24 hours and up +6.08% over the past month.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
See More
Previous Close:
$383.02
Open:
$382.74
24h Volume:
511.42K
Relative Volume:
1.09
Market Cap:
$27.03B
Revenue:
$3.22B
Net Income/Loss:
$542.70M
P/E Ratio:
51.34
EPS:
7.4805
Net Cash Flow:
$458.00M
1W Performance:
+4.92%
1M Performance:
+6.08%
6M Performance:
+42.33%
1Y Performance:
+43.73%
1-Day Range:
$380.28
$386.26
1-Week Range:
$363.10
$386.26
52-Week Range:
$223.83
$386.26
West Pharmaceutical Services Inc Stock (WST) Company Profile
Name
West Pharmaceutical Services Inc
Sector
Industry
Phone
(610) 594-2900
Address
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
384.02 | 27.03B | 3.22B | 542.70M | 458.00M | 7.4805 |
ISRG
Intuitive Surgical Inc
|
426.70 | 150.74B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
191.75 | 52.23B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
238.97 | 33.61B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
66.18 | 31.99B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.96 | 31.55B | 29.14B | 1.07B | 1.05B | 1.1956 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-26 | Resumed | UBS | Buy |
| Jul-13-26 | Initiated | BNP Paribas Exane | Outperform |
| Jun-09-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-02-26 | Resumed | Wolfe Research | Outperform |
| Dec-02-25 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-14-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-25 | Initiated | Citigroup | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-12-24 | Upgrade | UBS | Neutral → Buy |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-11-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Nov-30-22 | Initiated | UBS | Neutral |
| Oct-28-22 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-14-20 | Initiated | Stephens | Equal-Weight |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-24-20 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-12-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| May-01-19 | Downgrade | Jefferies | Buy → Hold |
| Apr-23-19 | Initiated | William Blair | Outperform |
| Apr-25-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-17-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-03-17 | Initiated | Stephens | Equal-Weight |
| Sep-15-17 | Upgrade | Jefferies | Hold → Buy |
| Oct-28-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Sep-21-16 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Mar-22-16 | Initiated | Wells Fargo | Outperform |
| May-14-10 | Reiterated | UBS | Neutral |
| Feb-23-10 | Initiated | Jefferies & Co | Buy |
| Dec-19-08 | Initiated | UBS | Neutral |
View All
West Pharmaceutical Services Inc Stock (WST) Latest News
Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’ - Benzinga
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms - Zacks Investment Research
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Here's Why You Should Retain WAT Stock in Your Portfolio for Now - Zacks Investment Research
Third-quarter results are due before markets open Oct. 29; West Pharmaceutical's call follows at 8 a.m. - Stock Titan
West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price (NYSE:WST) - Seeking Alpha
West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short - Yahoo Finance
West Pharmaceutical Services Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now - Zacks Investment Research
BDX Expands U.S. Manufacturing With $19B Healthcare Investment - Zacks Investment Research
Reasons to Hold HealthEquity Stock in Your Portfolio for Now - Zacks Investment Research
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies - Zacks Investment Research
West Pharmaceutical: Still A Buy, But Expectations Are Rising - Seeking Alpha
PCR Packaging For Pharma And Otc Market 7.2% CAGR to 2035 on ESG MandatesNews and Statistics - IndexBox
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal - TradingView
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - Zacks Investment Research
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - TradingView
Barclays Raises West Pharmaceutical Services Price Target to $440 From $400, Maintains Overweight Rating - marketscreener.com
West Pharmaceutical Services Highlights Leadership & Expertise - Contract Pharma
Is West Pharmaceutical Services Inc (WST) Overvalued After 3.2% - GuruFocus
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Reasons to Retain Doximity Stock in Your Portfolio for Now - Zacks Investment Research
What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report - Yahoo Finance
What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report - inkl
West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide - PR Newswire
Patient choice and drug-development risks are on the agenda for West's Milan talks - Stock Titan
A director receives 44 units payable in shares at West Pharmaceutical (WST), bringing her balance to 350.87. - Stock Titan
West Pharmaceutical Services Inc. stock outperforms competitors despite losses on the day - MarketWatch
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST) - Yahoo Finance
West Pharmaceutical Services (NYSE:WST) Stock Forecast & Analyst Predictions - Simply Wall Street
West Pharmaceutical Services, I (WST) Stock Forecasts - Yahoo Finance
West Pharmaceutical Services stock reports 13.80 percent revenue growth - AD HOC NEWS
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care - Zacks Investment Research
West Pharmaceutical Services stock attracts analyst coverage - AD HOC NEWS
West Pharmaceutical stock enters earnings watch with USD 382.00 target - AD HOC NEWS
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
What Comes Next for West Pharmaceutical Services (NYSE:WST)? - kalkinemedia.com
West Pharmaceutical Services stock gains after target rises - ad-hoc-news.de
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing - Zacks Investment Research
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says - marketscreener.com
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says - Yahoo Finance
West Pharmaceutical Services stock holds near its yearly range - AD HOC NEWS
Morgan Stanley Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $365 - Yahoo Finance
West Pharmaceutical Services Inc Stock (WST) Financials Data
Revenue
Net Income
Cash Flow
EPS
West Pharmaceutical Services Inc Stock (WST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 15 '26 |
Sale |
365.00 |
2,524 |
921,260 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 14 '26 |
Sale |
355.00 |
2,500 |
887,500 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Sale |
345.00 |
2,500 |
862,500 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Option Exercise |
89.64 |
2,500 |
224,100 |
24,318 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Option Exercise |
89.64 |
2,500 |
224,100 |
24,318 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 08 '26 |
Option Exercise |
85.37 |
8,135 |
694,453 |
19,663 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 08 '26 |
Sale |
340.81 |
8,135 |
2,772,489 |
16,845 |
| Hofmann Thomas W | Director |
May 07 '26 |
Proposed Sale |
322.12 |
3,384 |
1,090,051 |
0 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Sale |
300.67 |
896 |
269,399 |
1,523 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Option Exercise |
173.22 |
896 |
155,205 |
2,419 |
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):